updated 7/14/2009 1:34:06 PM ET 2009-07-14T17:34:06

Federal health regulators said Tuesday they are adding new labeling about the risks of infection to organ transplant drugs made by Roche, Novartis and other drugmakers.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The Food and Drug Administration said it has received reports of dangerous viral infections in patients taking the drugs, which are typically used to avoid rejection following kidney transplant.

Drugs bearing the new labeling are: Roche's CellCept, Wyeth's Rapamune, Novartis' Myfortic, Sandimmune and Neoral.

The FDA said physicians should carefully monitor patients for signs of viral infection, which can sometimes lead to kidney failure.

The agency said it will continue to monitor reports of safety problems with the medications.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments